6/3/2013

Diabetes drugs containing insulin glargine do not appear to increase the risk of cancer in patients, the European Medicines Agency's Committee for Medicinal Products for Human Use concluded. The committee reviewed two new cohort studies as well as studies from a search of the scientific literature.

Related Summaries